MCID: ONC002
MIFTS: 53

Onchocerciasis

Categories: Rare diseases, Infectious diseases

Aliases & Classifications for Onchocerciasis

MalaCards integrated aliases for Onchocerciasis:

Name: Onchocerciasis 12 72 49 55 51 3 41 14 69
River Blindness 49 3
Infection by Onchocerca Volvulus 12
Onchocerca Volvulus Infection 12
Onchocerciasis, Ocular 69
Robles' Disease 49
Volvulosis 12

Characteristics:

Orphanet epidemiological data:

55
onchocerciasis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 55  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11678
ICD10 32 B73
ICD9CM 34 125.3
MeSH 41 D009855
NCIt 46 C34861
SNOMED-CT 64 38539003
Orphanet 55 ORPHA2737
MESH via Orphanet 42 D009855 D015827
UMLS via Orphanet 70 C0029001 C0029002
ICD10 via Orphanet 33 B73

Summaries for Onchocerciasis

CDC : 3 Onchocerciasis, or River Blindness, is a neglected tropical disease (NTD) caused by the parasitic worm Onchocerca volvulus. It is transmitted through repeated bites by blackflies of the genus Simulium. The disease is called River Blindness because the blackfly that transmits the infection lives and breeds near fast-flowing streams and rivers and the infection can result in blindness. In addition to visual impairment or blindness, onchocerciasis causes skin disease, including nodules under the skin or debilitating itching. Worldwide onchocerciasis is second only to trachoma as an infectious cause of blindness.

MalaCards based summary : Onchocerciasis, also known as river blindness, is related to filariasis and schistosomiasis. An important gene associated with Onchocerciasis is RBP3 (Retinol Binding Protein 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ivermectin and Anticonvulsants have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and eye.

Disease Ontology : 12 A filariasis that involves parasitic infection caused by the nematode Onchocerca volvulus, which is transmitted to humans through the bite of a blackfly of the genus Simulium. The worms spread throughout the body and, when they die, cause intense itching and a strong immune system response that can destroy nearby tissue. The symptoms include pruritus, dermatitis, blindness, onchocercomata (subcutaneous nodules), and lymphadenopathy.

Wikipedia : 72 Onchocerciasis, also known as river blindness, is a disease caused by infection with the parasitic worm... more...

Related Diseases for Onchocerciasis

Diseases related to Onchocerciasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 162)
# Related Disease Score Top Affiliating Genes
1 filariasis 31.0 CCL5 IL2 IL5
2 schistosomiasis 29.7 IL13 IL2 IL4 IL5 RNASE3
3 tetanus 29.5 IL13 IL2 IL4 IL5
4 parasitic helminthiasis infectious disease 29.4 IL13 IL4 IL5 RNASE3
5 trypanosomiasis 29.2 CALR CCL5 IL2 IL4
6 leishmaniasis 29.2 IL13 IL4 IL5 MPI
7 urinary schistosomiasis 29.2 EPX IL13 IL4 IL5 RNASE3
8 dermatitis 28.4 CCL11 IL13 IL4 IL5 RNASE3
9 malaria 28.2 CCL11 CCL5 IL13 IL2 IL4 IL5
10 egg allergy 10.5 IL4 IL5
11 virus associated hemophagocytic syndrome 10.5 IL2 IL4
12 trichinosis 10.5 IL4 IL5
13 loeffler endocarditis 10.5 IL5 RNASE3
14 non-suppurative otitis media 10.5 IL4 IL5
15 scleritis 10.4 IL4 IL5
16 filarial elephantiasis 10.4
17 cow milk allergy 10.4 IL5 RNASE3
18 cercarial dermatitis 10.4 IL4 IL5
19 jak3-deficient severe combined immunodeficiency 10.4 IL2 IL4
20 maxillary sinusitis 10.4 CCL5 RNASE3
21 microscopic colitis 10.4 IL2 IL4
22 eosinophilic granuloma 10.4 EPX RNASE3
23 toxic oil syndrome 10.4 IL4 IL5
24 orofacial granulomatosis 10.4 CCL5 IL4
25 primary amebic meningoencephalitis 10.3 IL4 IL5
26 posterior uveitis 10.3 IL2 RBP3
27 epilepsy 10.3
28 cytokine deficiency 10.3 IL13 IL5
29 conjunctival nevus 10.3 EPX RNASE3
30 sinusitis 10.3 IL5 RNASE3
31 penicillin allergy 10.3 IL13 IL4
32 angioimmunoblastic lymphadenopathy with dysproteinemia 10.3 IL13 IL5
33 vulvovaginal candidiasis 10.3 IL2 IL4
34 cough variant asthma 10.3 IL4 IL5 RNASE3
35 eales disease 10.3 IL4 RBP3
36 intrinsic asthma 10.3 IL4 IL5 RNASE3
37 necatoriasis 10.3 CALR IL5
38 milk allergy 10.3 IL4 IL5 RNASE3
39 cellulitis 10.3 IL5 RNASE3
40 beta-lactam allergy 10.3 IL13 IL4
41 coccidiosis 10.3 IL2 IL4
42 paracoccidioidomycosis 10.3 IL2 IL4 IL5
43 sezary's disease 10.2 IL2 IL4 IL5
44 nut allergy 10.2 IL13 IL5
45 african tick-bite fever 10.2 CCL5 IL13
46 wells syndrome 10.2 IL2 IL5 RNASE3
47 allergic bronchopulmonary aspergillosis 10.2 EPX IL4 IL5
48 night blindness, congenital stationary, type 1a 10.2 IL13 IL5
49 loiasis 10.2
50 radiation cystitis 10.2 IL13 IL5

Graphical network of the top 20 diseases related to Onchocerciasis:



Diseases related to Onchocerciasis

Symptoms & Phenotypes for Onchocerciasis

Drugs & Therapeutics for Onchocerciasis

Drugs for Onchocerciasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ivermectin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 70288-86-7 46936176 6474909
2 Anticonvulsants Phase 4,Phase 2
3 Anti-Infective Agents Phase 4,Phase 3,Phase 2
4 Antiparasitic Agents Phase 4,Phase 3,Phase 2
5
Albendazole Approved, Vet_approved Phase 3 54965-21-8 2082
6 Vitamins Phase 3,Phase 2
7 Anthelmintics Phase 3,Phase 2,Phase 1
8 Antimitotic Agents Phase 3
9 Antiprotozoal Agents Phase 3,Phase 2
10 Milbemycin Phase 3,Phase 2
11
Phenytoin Approved, Vet_approved Phase 2 57-41-0 1775
12
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
13
Azithromycin Approved Phase 2 83905-01-5 53477736 447043 55185
14
Rifampin Approved Phase 2 13292-46-1 5381226 5458213
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
16
Pyridoxal Approved, Nutraceutical Phase 2 66-72-8 1050
17
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 2 65-23-6 1054
18 Antimanic Agents Phase 2
19 Central Nervous System Depressants Phase 2
20 Diuretics, Potassium Sparing Phase 2
21 GABA Agents Phase 2
22 Micronutrients Phase 2
23 Neurotransmitter Agents Phase 2
24 Psychotropic Drugs Phase 2
25 Sodium Channel Blockers Phase 2
26 Trace Elements Phase 2
27 Tranquilizing Agents Phase 2
28 Vitamin B 6 Phase 2
29 Vitamin B Complex Phase 2
30 Anti-Bacterial Agents Phase 2
31 Antibiotics, Antitubercular Phase 2
32 Antitubercular Agents Phase 2
33 Cytochrome P-450 CYP3A Inducers Phase 2
34 Nucleic Acid Synthesis Inhibitors Phase 2
35 Antimalarials Phase 2
36 Artemisinine Phase 2
37 Artemisinins Phase 2
38
Dihydroartemisinin Phase 2 71939-50-9 6918483
39
Piperaquine Phase 2 4085-31-8 5079497
40 Imatinib Mesylate Phase 2 123596
41 Protein Kinase Inhibitors Phase 2
42 Folate Nutraceutical Phase 2
43 Vitamin B9 Nutraceutical Phase 2
44
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
45
Diethylcarbamazine Approved, Investigational, Vet_approved 90-89-1 3052
46
Mebendazole Approved, Vet_approved 31431-39-7 4030
47
Piperazine Approved, Vet_approved 110-85-0 4837
48
Suramin Approved, Investigational 145-63-1 5361
49
Citric Acid Approved, Nutraceutical, Vet_approved 77-92-9 311
50 Lipoxygenase Inhibitors

Interventional clinical trials:

(show all 19)

# Name Status NCT ID Phase Drugs
1 Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy Not yet recruiting NCT03052998 Phase 4 Ivermectin
2 IVM Alone vs ALB + IVM Against Onchocerciasis Completed NCT03238131 Phase 3 Ivermectin;Albendazole
3 Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection Completed NCT00790998 Phase 3 Moxidectin;Ivermectin
4 Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana Active, not recruiting NCT02078024 Phase 3 IVM plus ALB;IVM
5 Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda — 2012 Unknown status NCT01730313 Phase 2 Pyridoxine;Sodium Valproate;Phenytoin;Placebo
6 Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection Completed NCT00300768 Phase 2 2 mg moxidectin;ivermectin 150 mcg/kg;4 mg moxidectin;8 mg moxidectin
7 Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness Completed NCT00127504 Phase 2 Rifampin;Azithromycin
8 Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study Completed NCT02511353 Phase 2 ivermectin;placebo;dihydroartemisinin-piperaquine
9 Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa Not yet recruiting NCT02644525 Phase 2 Imatinib Mesylate;Placebo
10 Pediatric Pharmacokinetics And Safety Study Of Moxidectin Withdrawn NCT01035619 Phase 2 moxidectin
11 First in Man Clinical Trial of Emodepside (BAY 44-4400) Completed NCT02661178 Phase 1 emodepside (BAY 44-4400);placebo
12 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole and diethylcarbamazine
13 Community Directed Treatment of Soil-Transmitted Helminths Among Young Children in Zambia Completed NCT00349323
14 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast) Recruiting NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
15 Host Response to Infection and Treatment in Filarial Diseases Recruiting NCT00001230
16 Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia Active, not recruiting NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
17 Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis Active, not recruiting NCT02899936 3 drug dose - IDA;2 drug dose - DA
18 Lymphatic Filariasis (LF) in Ivory Coast Active, not recruiting NCT02974049 Albendazole;Ivermectin;Diethylcarbamazine
19 Prevalence of LF Infection in Districts Not Included in LF Control Activities Not yet recruiting NCT03131401

Search NIH Clinical Center for Onchocerciasis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: onchocerciasis

Genetic Tests for Onchocerciasis

Anatomical Context for Onchocerciasis

MalaCards organs/tissues related to Onchocerciasis:

38
Skin, Testes, Eye, Neutrophil, T Cells, Breast, Lymph Node

Publications for Onchocerciasis

Articles related to Onchocerciasis:

(show top 50) (show all 677)
# Title Authors Year
1
Onchocerciasis associated epilepsy: An important neglected public health problem. ( 29325732 )
2018
2
Sara Lustigman: Developing a vaccine to accelerate onchocerciasis elimination. ( 29174373 )
2018
3
Serious Neurological Adverse Events after Ivermectin-Do They Occur beyond the Indication of Onchocerciasis? ( 29210346 )
2018
4
Author Correction: Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis. ( 29348597 )
2018
5
Geographical distribution and species identification of human filariasis and onchocerciasis in Bioko Island, Equatorial Guinea. ( 29289559 )
2018
6
"Cross-border collaboration in onchocerciasis elimination in Uganda: progress, challenges and opportunities from 2008 to 2013". ( 29409509 )
2018
7
Important progress towards elimination of onchocerciasis in the West Region of Cameroon. ( 28774318 )
2017
8
Adherence to ivermectin is more associated with perceptions of community directed treatment with ivermectin organization than with onchocerciasis beliefs. ( 28806785 )
2017
9
Application of optimal control to the onchocerciasis transmission model with treatment. ( 29175094 )
2017
10
River-specific macrogenomic diversity in Simulium guianense s. l. (Diptera: Simuliidae), a complex of tropical American vectors associated with human onchocerciasis. ( 28727841 )
2017
11
Evaluation of Onchocerciasis Transmission in Tanzania: Preliminary Rapid Field Results in the Tukuyu Focus, 2015. ( 28722619 )
2017
12
A new methodology for sampling blackflies for the entomological surveillance of onchocerciasis in Brazil. ( 28727733 )
2017
13
Modelling the health and economic impacts of the elimination of river blindness (onchocerciasis) in Africa. ( 28589011 )
2017
14
The Genomic Architecture of Novel Simulium damnosum Wolbachia Prophage Sequence Elements and Implications for Onchocerciasis Epidemiology. ( 28611731 )
2017
15
Dermatological manifestations in onchocerciasis: A retrospective study of 400 imported cases. ( 29275076 )
2017
16
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa. ( 28056015 )
2017
17
For as long as necessary: examining 30 years of Merck & Co., Inc.'s focus on achieving elimination of onchocerciasis and lymphatic filariasis. ( 29186497 )
2017
18
Comparison of Doxycycline, Minocycline, Doxycycline plus Albendazole and Albendazole Alone in Their Efficacy against Onchocerciasis in a Randomized, Open-Label, Pilot Trial. ( 28056021 )
2017
19
681 Progress report on the elimination of human onchocerciasis, 2016a892017. ( 29130679 )
2017
20
Programmatic factors associated with the limited impact of Community-Directed Treatment with Ivermectin to control Onchocerciasis in three drainage basins of South West Cameroon. ( 29155826 )
2017
21
Review of Ethiopian Onchocerciasis Elimination Programme. ( 28878430 )
2017
22
Biodiversity of Simulium metallicum sensu lato (Diptera: Simuliidae), a complex of Neotropical vectors associated with human onchocerciasis. ( 28624513 )
2017
23
Unravelling the mysterious onchocerciasis-nodding syndrome link: new developments and future challenges. ( 29299448 )
2017
24
Is imported onchocerciasis a truly rare entity? Case report and review of the literature. ( 28232074 )
2017
25
The Current Status of Molecular Xenomonitoring for Lymphatic Filariasis and Onchocerciasis. ( 28756911 )
2017
26
Progress towards eliminating onchocerciasis in the WHO Region of the Americas: elimination of transmission in the north-east focus of the Bolivarian Republic of Venezuela. ( 29028167 )
2017
27
Ivermectin Treatment in Patients With Onchocerciasis-Associated Epilepsy: Protocol of a Randomized Clinical Trial. ( 28855148 )
2017
28
O-5S quantitative real-time PCR: a new diagnostic tool for laboratory confirmation of human onchocerciasis. ( 28969662 )
2017
29
Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis. ( 28303006 )
2017
30
Feasibility of utilizing the SD BIOLINE Onchocerciasis IgG4 rapid test in onchocerciasis surveillance in Senegal. ( 28972982 )
2017
31
River blindness goes beyond the eye: autoimmune antibodies, cross-reactive with<i>Onchocerca volvulus</i>antigen, detected in brain of patients with Nodding syndrome. ( 29285492 )
2017
32
Evaluation of Community-Directed Operation of Black Fly Traps for Entomological Surveillance of Onchocerca volvulus Transmission in the Madi-Mid North Focus of Onchocerciasis in Northern Uganda. ( 28820716 )
2017
33
Validation of onchocerciasis biomarker N-acetyltyramine-O-glucuronide (NATOG). ( 28600214 )
2017
34
Skin snips have no role in programmatic evaluations for onchocerciasis elimination: a reply to Bottomley et al. ( 28335815 )
2017
35
Onchocerciasis-Associated Epilepsy, an Additional Reason for Strengthening Onchocerciasis Elimination Programs. ( 29288080 )
2017
36
A Test-and-Not-Treat Strategy for Onchocerciasis in Loa loa-Endemic Areas. ( 29116890 )
2017
37
Evaluation of Community-Directed Operation of Black Fly Traps for Entomological Surveillance of<i>Onchocerca volvulus</i>Transmission in the Madi-Mid North Focus of Onchocerciasis in Northern Uganda. ( 29031285 )
2017
38
Loa loa vectors Chrysops spp.: perspectives on research, distribution, bionomics, and implications for elimination of lymphatic filariasis and onchocerciasis. ( 28381279 )
2017
39
Onchocerciasis in the Democratic Republic of Congo: Survey of knowledge, attitude and perception in Bandundu province. ( 28215917 )
2017
40
Recrudescence of onchocerciasis in the ComoAc valley in Southwest Burkina Faso. ( 27845063 )
2017
41
The esperanza window trap reduces the human biting rate of Simulium ochraceum s.l. in formerly onchocerciasis endemic foci in Southern Mexico. ( 28686665 )
2017
42
High prevalence of epilepsy in onchocerciasis endemic regions in the Democratic Republic of the Congo. ( 28708828 )
2017
43
Assessment of the performance of community-directed treatment with ivermectin strategy for the control and elimination of onchocerciasis in Edo State, Nigeria. ( 29219132 )
2017
44
Wolbachia endosymbionts induce neutrophil extracellular trap formation in human onchocerciasis. ( 27752109 )
2016
45
Comparison of a new visual isothermal nucleic acid amplification test with PCR and skin snip analysis for diagnosis of onchocerciasis in humans. ( 27473357 )
2016
46
Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results. ( 27349645 )
2016
47
Still mesoendemic onchocerciasis in two Cameroonian community-directed treatment with ivermectin projects despite more than 15 years of mass treatment. ( 27842567 )
2016
48
A Knowledge, Attitudes and Practices Survey Conducted Three Years after Halting Ivermectin Mass Treatment for Onchocerciasis in Guatemala. ( 27341104 )
2016
49
Progress towards eliminating onchocerciasis in the WHO Region of the Americas: verification of elimination of transmission in Guatemala. ( 27801556 )
2016
50
Onchocerciasis, an undiagnosed disease in Mozambique: identifying research opportunities. ( 27030247 )
2016

Variations for Onchocerciasis

Expression for Onchocerciasis

Search GEO for disease gene expression data for Onchocerciasis.

Pathways for Onchocerciasis

Pathways related to Onchocerciasis according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 CALR CCL11 CCL5 EPX IL13 IL2
2
Show member pathways
13.66 CCL11 CCL5 CCL7 IL13 IL2 IL4
3
Show member pathways
13.49 CCL11 CCL5 CCL7 IL13 IL2 IL4
4
Show member pathways
13.38 CCL11 CCL5 CCL7 IL13 IL2 IL4
5
Show member pathways
13.25 CCL11 CCL5 CCL7 IL13 IL2 IL4
6
Show member pathways
13.2 CCL11 CCL5 IL13 IL2 IL4 IL5
7
Show member pathways
13.13 CCL11 CCL5 CCL7 IL13 IL2 IL4
8
Show member pathways
12.72 CALR CCL11 CCL5 CCL7
9 12.68 IL13 IL2 IL4 IL5
10
Show member pathways
12.64 CCL5 IL13 IL2 IL4
11
Show member pathways
12.46 IL13 IL2 IL4 IL5
12
Show member pathways
12.3 CALR CCL11 EPX IL13 IL2 IL4
13
Show member pathways
12.25 IL13 IL2 IL4 IL5
14
Show member pathways
12.19 CCL11 CCL7 IL13 IL4 IL5
15
Show member pathways
12.02 IL13 IL2 IL4 IL5
16
Show member pathways
11.91 IL13 IL2 IL5
17
Show member pathways
11.88 CCL11 CCL5 CCL7
18 11.87 IL2 IL4 IL5
19 11.86 CCL11 IL13 IL4
20 11.71 IL13 IL2 IL4 IL5
21 11.68 IL13 IL2 IL4 IL5
22
Show member pathways
11.65 IL2 IL4 IL5
23 11.56 CCL11 IL4 IL5
24 11.45 CCL11 CCL5 IL13 IL4 IL5
25 11.44 CCL5 IL13 IL4
26 11.24 IL2 IL4 IL5
27 11.22 IL13 IL4 IL5
28 11.22 CCL11 IL13 IL2 IL4 IL5
29 11.15 IL13 IL2 IL4 IL5
30 11.1 IL13 IL2
31 11.04 IL13 IL2 IL4 IL5
32 10.85 CCL11 CCL5 CCL7 IL13 IL2 IL4
33 10.69 IL13 IL4 IL5
34 10.4 CCL11 CCL5 CCL7 IL13 IL2 IL4

GO Terms for Onchocerciasis

Cellular components related to Onchocerciasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 CALR CCL11 CCL5 CCL7 EPX IL13
2 extracellular space GO:0005615 9.36 CALR CCL11 CCL5 CCL7 EPX IL13
3 cell GO:0005623 9.33 CCL11 CCL7 IL2

Biological processes related to Onchocerciasis according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.88 CCL5 CCL7 IL13 IL2
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.8 CCL11 CCL5 CCL7
3 positive regulation of cell migration GO:0030335 9.79 CCL11 CCL5 CCL7
4 cellular response to tumor necrosis factor GO:0071356 9.77 CCL11 CCL5 CCL7
5 inflammatory response GO:0006954 9.77 CCL11 CCL5 CCL7 IL13 IL5
6 cellular response to interferon-gamma GO:0071346 9.74 CCL11 CCL5 CCL7
7 cellular response to interleukin-1 GO:0071347 9.72 CCL11 CCL5 CCL7
8 chemokine-mediated signaling pathway GO:0070098 9.71 CCL11 CCL5 CCL7
9 chemotaxis GO:0006935 9.71 CCL11 CCL5 CCL7 IL4
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.7 CCL5 IL13 IL2
11 neutrophil chemotaxis GO:0030593 9.69 CCL11 CCL5 CCL7
12 positive regulation of T cell proliferation GO:0042102 9.65 CCL5 IL2 IL4
13 monocyte chemotaxis GO:0002548 9.63 CCL11 CCL5 CCL7
14 cellular calcium ion homeostasis GO:0006874 9.62 CALR CCL11 CCL5 CCL7
15 negative regulation of endothelial cell apoptotic process GO:2000352 9.61 IL13 IL4
16 positive regulation of JAK-STAT cascade GO:0046427 9.61 CCL5 IL5
17 positive regulation of T cell differentiation GO:0045582 9.6 IL2 IL4
18 positive regulation of immunoglobulin secretion GO:0051024 9.58 IL2 IL5
19 positive regulation of isotype switching to IgG isotypes GO:0048304 9.56 IL2 IL4
20 immune response GO:0006955 9.5 CCL11 CCL5 CCL7 IL13 IL2 IL4
21 positive regulation of natural killer cell chemotaxis GO:2000503 9.49 CCL5 CCL7
22 positive regulation of B cell proliferation GO:0030890 9.46 IL13 IL2 IL4 IL5
23 negative regulation of complement-dependent cytotoxicity GO:1903660 9.43 IL13 IL4
24 eosinophil chemotaxis GO:0048245 9.43 CCL11 CCL5 CCL7
25 regulation of receptor activity GO:0010469 9.17 CCL11 CCL5 CCL7 IL13 IL2 IL4

Molecular functions related to Onchocerciasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.43 IL2 IL4 IL5
2 cytokine receptor binding GO:0005126 9.32 IL13 IL4
3 cytokine activity GO:0005125 9.17 CCL11 CCL5 CCL7 IL13 IL2 IL4
4 CCR1 chemokine receptor binding GO:0031726 9.16 CCL5 CCL7
5 chemokine activity GO:0008009 9.13 CCL11 CCL5 CCL7

Sources for Onchocerciasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....